Sa1992 SFRS2 and CDC5L Interaction: An insight Into Downstream Events Following APC Deletion During Colorectal Carcinogenesis

Ibrahim, S. A.; Reed, Karen Ruth; Clarke, Alan R.; Pritchard, D. Mark; Jenkins, Jennifer

doi:10.1016/s0016-5085(13)61301-3

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the top upregulated proteins included myosin-7 (MYH7) which is related to eukaryotic cell motility; CD166 (ALCAM) has been regarded as a potential cancer stem cell marker (15). Splicing factor, arginine/serine-rich 2 (SFRS2) demonstrated Wnt signaling-dependent activation which promotes cell migration (16); and Ras-related protein Rab-11A (RAB11A) can differentially modulate epidermal growth factor-induced proliferation and motility in immortal breast cells (17). These newly identified upregulated molecules in recurrent chordomas by our analysis may be possible biomarkers for diagnosis and/ or targets for treating recurrent chordomas.…”

Section: Resultsmentioning

confidence: 99%

Differential proteomic profiling of primary and recurrent chordomas

Chen

Jiao

et al. 2015

Oncology Reports

View full text Add to dashboard Cite

Chordomas are locally destructive tumors with high rates of recurrence and a poor prognosis. The mechanisms involved in chordoma recurrence remain largely unknown. In the present study, we examined the proteomic profile of a chordoma primary tumor (CSO) and a recurrent tumor (CSR) through mass spectrum in a chordoma patient who underwent surgery. Bioinformatic analysis of the profile showed that 359 proteins had a significant expression difference and 21 pathways had a striking alteration between the CSO and the CSR. The CSR showed a significant increase in carbohydrate metabolism. Immunohistochemistry (IHC) confirmed that the cancer stem cell marker activated leukocyte cell adhesion molecule (ALCAM or CD166) expression level was higher in the recurrent than that in the primary tumor. The present study analyzed the proteomic profile change between CSO and CSR and identified a new biomarker ALCAM in recurrent chordomas. This finding sheds light on unraveling the pathophysiology of chordoma recurrence and on exploring more effective prognostic biomarkers and targeted therapies against this devastating disease.

show abstract

Section: Resultsmentioning

confidence: 99%